Novo Nordisk (NVO) has released an update.
Novo Nordisk has announced successful phase 2a clinical trial results for monlunabant, its oral obesity treatment, showing significant weight loss compared to placebo. The drug, acquired through the purchase of Inversago Pharmaceuticals, demonstrated both efficacy and a dose-dependent safety profile, with plans to initiate a phase 2b trial in 2025. This development is a promising step in addressing the unmet needs in obesity treatment.
For further insights into NVO stock, check out TipRanks’ Stock Analysis page.
